ThromboGenics : Business Update – Q1 2016

Highlights

• ThromboGenics is focused on developing novel medicines for the treatment of diabetic eye disease

• ThromboGenics presented its new drug development pipeline with 4 compounds, targeting novel treatments for diabetic retinopathy (DR) - non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), in the presence or absence of diabetic macular edema (DME)

• ThromboGenics initiated a Phase IIa clinical study (CIRCLE) evaluating THR-409 (ocriplasmin) to induce a complete posterior vitreous detachment (PVD), to prevent patients with non-proliferative diabetic retinopathy from progressing to proliferative diabetic retinopathy, a serious sight threatening condition

• ThromboGenics signed a global and exclusive license agreement with Galapagos to develop and commercialize integrin antagonists for the treatment of diabetic eye disease. The Company has started to explore the potential of these compounds for the treatment of NPDR and PDR

• Full report of OASIS 2 year follow up study with JETREA® (ocriplasmin) for the treatment of symptomatic VMA/VMT and Macular Hole (n=220) has been submitted and accepted for publication in a prestigious peer reviewed ophthalmology journal

• 15 ocriplasmin-related posters and presentations, with new research findings, were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting in Seattle

• Following a collaboration agreement with the US-based NMTRC (Neuroblastoma and Medulloblastoma Translational Research Center), ThromboGenics' subsidiary, Oncurious, has initiated a Phase I/IIa study with TB-403 for the treatment of medulloblastoma, the most common pediatric malignant brain tumor

• Cash and investments were €96.9 million as of the end of March 2016, compared with €101.4 million at the end of December 2015

Leuven, Belgium - 13th May 2016 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for diabetic eye disease, today issues a business update for the three month period ending 31 March, 2016.

ThromboGenics is focused on developing novel medicines for diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME).

Over the last two years, ThromboGenics has developed an attractive pipeline of disease modifying drug candidates. The pipeline consists of THR-409, THR-317, both from its in-house research, as well as THR-149 which resulted from a research collaboration with Bicycle Therapeutics, and THR-687, which was recently in-licensed from Galapagos NV.

These products all have different modes of action and allow the Company to address the four key segments of the evolving diabetic eye disease market:

• Non-proliferative DR
• Proliferative DR
• Non-proliferative DR with DME
• Proliferative DR with DME

ThromboGenics believes its diabetic eye disease pipeline is one of the strongest in the industry.

In addition, ThromboGenics, through its oncology spin-off Oncurious, is conducting a Phase I/IIa clinical trial in children assessing TB-403 for the treatment of medullablastoma, the most common malignant brain tumor in children. This oncological development program is jointly conducted with ThromboGenics' research partner BioInvent International AB.

Dr. Patrik De Haes, ThromboGenics' CEO, said: 'ThromboGenics has entered a new era as we progress our exciting drug development pipeline of potential new disease modifying medicines for the treatment of diabetic eye disease. Diabetic Retinopathy and Diabetic Macular Edema (DME) are significant indications where there are clear unmet medical needs and a strong demand for improved or add-on treatment options. With our ambitious pipeline, we believe we are well positioned to address all key segments of the diabetic eye disease market and to generate attractive returns for our shareholders.'